NCT00297063View on ClinicalTrials.gov

BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-

PHASE3CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

January 11, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Rosiglitazone

Trial Locations (14)

819-0168

GSK Investigational Site, Fukuoka

962-0856

GSK Investigational Site, Fukushima

051-0005

GSK Investigational Site, Hokkaido

311-0113

GSK Investigational Site, Ibaraki

224-0024

GSK Investigational Site, Kanagawa

615-0035

GSK Investigational Site, Kyoto

399-0006

GSK Investigational Site, Nagano

577-0803

GSK Investigational Site, Osaka

349-1105

GSK Investigational Site, Saitama

424-0855

GSK Investigational Site, Shizuoka

125-0054

GSK Investigational Site, Tokyo

130-0004

GSK Investigational Site, Tokyo

160-0017

GSK Investigational Site, Tokyo

Unknown

GSK Investigational Site

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY